Ontology highlight
ABSTRACT:
SUBMITTER: Aledort L
PROVIDER: S-EPMC6917528 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
Aledort Louis L Mannucci Pier Mannuccio PM Schramm Wolfgang W Tarantino Michael M
Blood transfusion = Trasfusione del sangue 20191101 6
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management ...[more]